Drug Topics
AUGUST 26, 2022
Although further studies are needed to confirm the long-term effects, recent studies have shown the infliximab biosimilar to be a safe, effective, and cost reducing treatment for inflammatory bowel diseases.
Pharmacy Times
AUGUST 23, 2022
Francesca Ceddia, MD, senior vice president of respiratory vaccines at Moderna, said the company is in early stages of development for a combined mRNA vaccine for influenza, COVID-19, and RSV.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
AUGUST 25, 2022
Following numerous recalls, the industry is striving to investigate the causes, sources and ways to mitigate carcinogenic nitrosamine impurities. In a recent paper, published in the International Journal of Pharmaceutics , researchers identified nitrocellulose blister packaging as a potential source of N -nitrosodimethylamine (NDMA) and N -nitrosodiethylamine (NDEA) impurities.
PhRMA
AUGUST 25, 2022
Too many patients face high out-of-pocket costs for brand medicines, even when they have insurance.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Drug Topics
AUGUST 25, 2022
Researchers report that half of the online pharmacies are rogue operations that may operate without a license or have other serious shortcomings.
Pharmacy Times
AUGUST 24, 2022
Analysis includes nearly 43 million individuals aged 13 year and older who received at least 1 dose in England between December 1, 2020, and December 15, 2021.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
pharmaphorum
AUGUST 24, 2022
The FDA has given a novel anticoagulant from Merck & Co a fast-track designation as a treatment for people with end-stage renal disease (ESRD) who need dialysis, firing a warning short over the bows of a rival programme in development at Ionis and Bayer. The anticoagulant – codenamed MK-2060 – is a monoclonal antibody designed to inhibit Factor XI and is currently in a phase 2b trial in ESRD patients on dialysis, who often need to be treated with anticoagulants to prevent blood clots.
Drug Topics
AUGUST 26, 2022
Medicare users will see prescription drug pricing reform thanks to the Inflation Reduction Act.
Pharmacy Times
AUGUST 26, 2022
Additionally, approximately 70% who responded to the EnlivenHealth survey say that one-third or more of their revenue comes from individuals eligible for the government health insurance.
Pharmaceutical Technology
AUGUST 25, 2022
The European Commission (EC) has granted conditional marketing authorisation (CMA) for BioMarin Pharmaceutical ’s gene therapy, Roctavian (valoctocogene roxaparvovec), to treat adults with severe haemophilia A (congenital Factor VIII deficiency). The treatment is indicated for patients with no history of Factor VIII inhibitors and any detectable antibodies to adeno-associated virus serotype 5 (AAV5).
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
AUGUST 23, 2022
France’s BrainVectis, a subsidiary of Bayer’s Asklepios BioPharma (AskBio) unit, has been given the green light by regulators in France to start dosing patients with its gene therapy candidate for devastating neurodegenerative disorder Huntington’s disease. The phase 1/2 study is due to get underway before the end of the year and will test BrainVectis’ one-shot BV-101 gene therapy, which will be delivered using an adeno-associated virus (AAV) vector directly to areas of
Drug Topics
AUGUST 25, 2022
What are the long term psychiatric and neuropsychiatric complications of COVID-19?
Pharmacy Times
AUGUST 25, 2022
As pharmacists take on new responsibilities, researchers have been studying the effects of pharmacists on interprofessional care teams.
Outsourcing Pharma
AUGUST 23, 2022
The groupâs latest report glimpses inside the minds of pharma leaders, who are looking at a productâs full life-cycle development at the preclinical stage.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
PharmaVoice
AUGUST 23, 2022
PsychoGenics is leveraging AI-driven drug discovery platforms to advance mental health treatments for schizophrenia, bipolar disorder and treatment-resistant depression.
Drug Topics
AUGUST 25, 2022
With the evolution of different COVID-19 variants, finding the mean incubation period has become more complex.
Pharmacy Times
AUGUST 25, 2022
During the surge caused by the Delta variant, a third dose of the Pfizer-BioNTech COVID-19 vaccine reduced infections and COVID-19-related hospitalizations and deaths among patients in long term care facilities.
pharmaphorum
AUGUST 23, 2022
Japan’s Takeda has secured its first regulatory approval – in Indonesia – for its dengue fever vaccine TAK-003, which has been tipped as a potential blockbuster product. Indonesia’s National Agency for Drug and Food Control (BPOM) has approved the vaccine as Qdenga to protect against the virus in people aged six to 45, on the back of data showing that it can cut dengue-related hospitalisations by 84%, with 61% protective efficacy against symptomatic illness seen up to three years aft
Board Vitals - Pharmacist
AUGUST 26, 2022
The American Board of Psychiatry and Neurology (ABPN) Certification Exam in Child Neurology is a board examination that tests a candidate’s knowledge of the fundamentals of child neurology. The exam is held once a year, and is required to become board certified in Child Neurology. We’ve compiled some of the most frequently asked questions about the test.
Pharmaceutical Technology
AUGUST 26, 2022
The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) is banking on a collaborative approach to scientific innovation to address the growing problem of drug resistance in tuberculosis (TB). Last week, the collaborative announced that it is executing a joint development agreement (JDA) to advance two novel drug regimens to Phase II clinical trials by 2023.
Pharmacy Times
AUGUST 22, 2022
University of Minnesota Medical School Analysis shows comparison with fluvoxamine and ivermectin in a double-blinded, placebo-controlled, randomized study.
DiversifyRx
AUGUST 25, 2022
If you missed the Day 1 Pharmacy Profit Summit recap, you can catch it here. Day 2 was packed with even more speakers that gave critical information on how to grow your profits with various solutions. Let’s dive into day two and get the specific information you need. Dr. Lisa Faast. Dr. Faast started by welcoming everyone back and sharing information about projects and offers for attendees.
pharmaphorum
AUGUST 25, 2022
Amazon’s ambitious plan to disrupt the healthcare category seems to have had a course correction after the online retail giant announced it plans to shut down its telehealth service Amazon Care. It’s a dramatic change in direction, coming just a few months after Amazon was trumpeting its intention to make the three-year-old telehealth service available to employers nationwide in the US.
BuzzRx
AUGUST 24, 2022
Deep brain stimulation (DBS) is one of the surgical treatments performed to treat Parkinson's disease. It involves the placement of a deep brain stimulator (metal wires in the brain connected to a pulse generator in the chest). Abnormal electrical signals in the brain cause the motor complications seen in Parkinson’s disease. Deep brain stimulation works by regulating electrical stimulation in certain parts of the brain.
Pharmacy Times
AUGUST 26, 2022
Pemigatinib is the first targeted therapy to gain FDA approval for the treatment of adult patients with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.
The Guardian - Pharmaceutical Industry
AUGUST 20, 2022
After a year on prescription stimulants, I started to unravel. Would a desperate experiment with street narcotics make me see things differently? At first being diagnosed with ADHD came as a relief. I cried in the psychiatrist’s office: maybe I wasn’t lazy after all. He gave me pills that, within days, offered me a glimpse of what I thought a neurotypical person’s brain might feel like: focused and smooth, like a game of leisurely tennis rather than a ball machine going berserk.
pharmaphorum
AUGUST 25, 2022
For most of my adult life, I had been the typical American fat guy, gaining a pound or two a year and thinking little of it. That was until my doctors stunned me with the news that I had cirrhosis caused by non-alcoholic steatohepatitis, or NASH, a severe form of fatty liver disease that often has few or no symptoms until very late stages. I had never heard of NASH, and I was even more shocked when I started searching online and discovered the prevalence of the disease and the tragic reality tha
The FDA Law Blog
AUGUST 23, 2022
By Lisa M. Baumhardt, Senior Medical Device Regulation Expert & Richard A. Lewis, Senior Regulatory Device & Biologics Expert — We are almost three years into the public health emergency as a result of the COVID-19 pandemic, and still only have 19 rapid antigen tests authorized for at-home use in the United States. The primary barrier to bringing new antigen tests to market has been FDA’s minimum requirement of 80% sensitivity for authorization.
Pharmacy Times
AUGUST 26, 2022
Yoona Kim, PharmD, PhD, co-founder and CEO of Arine, discusses some of the key takeaways from the launch of Mark Cuban's pharmacy Mark Cuban Cost Plus Drug Co.
The Honest Apothecary
AUGUST 26, 2022
I am convinced that one of the reasons why so many healthcare professionals struggle when transitioning to management roles is the sheer messiness of it all. Medical folks are trained to insist upon good order, and rightly so. Chaos is the enemy of workplace safety and patient care. Doctors, nurses, and pharmacists generally prefer consistent and well-defined workflows and have a low tolerance for ambiguity.
Drug Store News
AUGUST 25, 2022
The donations support the work of healthcare providers and amplify the impact community organizations have on meeting the needs of families with individuals who have intellectual or developmental disabilities.
pharmaphorum
AUGUST 25, 2022
Johnson & Johnson has its first worldwide regulatory approval – in the EU – for Tecvayli, one of two much-anticipated bispecific antibodies the drugmaker has developed for patients with multiple myeloma. The double-headed antibody binds to CD3 on T cells and redirects them to BCMA-expressing myeloma cells, with the aim of stimulating an immune attack on the tumour, which remains incurable despite a slew of new therapies reaching the market in recent years.
Pharmacy Times
AUGUST 26, 2022
The FDA has approved glycopyrrolate orally disintegrating tablets (Dartisla ODT; Edenbridge Pharmaceuticals) to reduce symptoms of peptic ulcer as an adjunct to peptic ulcer treatment in adults.
PharmaVoice
AUGUST 22, 2022
The rare disease veteran and first-time CEO is bringing his expertise to the company as it launches the first FDA-approved treatment for pyruvate kinase (PK) deficiency.
Expert insights. Personalized for you.
184 
Let's personalize your content